ReviewCell and tissue banking2026
Cryopreservation of adipose tissue for nanofat production: biological principles, workflow standardisation, and regulated biobanking.
Review in Cell and tissue banking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanofat, produced through mechanical processing of autologous adipose tissue, contains stromal vascular fraction (SVF), extracellular matrix components, and perivascular cell populations associated with paracrine, angiogenic, and immunomodulatory signalling. Cryopreservation before emulsification allows material from a single harvest to be stored and used across multiple treatments, supporting staged clinical, reconstructive, and tissue-support applications. This reduces patient burden and the morbidity of repeated liposuction, and potentially enables treatment schedules to align with tissue remodelling cycles.The cryobiology of adipose tissue and the biological properties of SVF-derived preparations are each well characterised in isolation, but the literature lacks a coherent account of how they combine in a workflow that is both clinically practical and compatible with regulatory oversight. Most published approaches describe same-day preparation, offering little structure for staged treatments without repeated harvest. This article synthesises current evidence on nanofat biology, cryobiology principles for adipose-derived preparations, mechanical processing and delivery, and governance requirements for regulated cryostorage. A generic Human Tissue Authority (HTA)-licensed cryopreservation workflow model is presented to illustrate how validated controlled-rate freezing, cryopreservation of whole lipoaspirate, thawing, and mechanical emulsification to produce nanofat, supported by traceability and a documented quality management system (QMS), can support regulated clinical use. This article addresses a gap in the literature by providing a structured pathway for consistent autologous treatments from a single harvest while meeting regulatory expectations for human tissue storage. This article is a narrative synthesis, not a systematic review; it focuses on workflow, cryobiological, and governance conditions rather than grading therapeutic efficacy.
Indexed as
Identifiers
42881282What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.